Log in with your email address username.


[Correspondence] What must be the role of INSERM in French biomedical research?

The major criticism raised in an Editorial (June 16, p 2390)1 was the suggestion that the renewal of the Chief Executive Officer (CEO) at the French National Institute of Health and Medical Research (INSERM) lacks transparency, since the candidates for the position are not known. This suggests that the practice does not support an “open and transparent nomination process”.1 One must remember that in France, candidates are protected by the legal framework; they are auditioned and judged by a jury, and a candidate is proposed to the appropriate ministry.